Stocks Health care SLDB
NASDAQ · Health careSolid Biosciences Inc. (SLDB)
It posted a net loss of $215.3M. In fiscal 2025 capital spending exceeded operating cash flow by $157.4M. At September 30, 2026 it held $126M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 4, 2026.
Key facts about Solid Biosciences Inc.
- Net worth
- Solid Biosciences Inc. has a market value (market cap) of $752.7M at the latest share price, and shareholders' equity of $342.1M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2022 revenue was $8.1M (-40.6% year on year), with a net loss of $86M.
- Cash flow
- In fiscal 2025 operations used $156.3M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 4, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
What Solid Biosciences Inc. does
Solid Biosciences Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker SLDB.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$174.3M | -$1.99 | -$157.4M |
| 2024 | n/a | -$124.7M | -$3.06 | -$100.7M |
| 2023 | n/a | -$96M | -$4.83 | -$95.7M |
| 2022 | $8.1M | -$86M | -$10.10 | -$101M |
| 2021 | $13.6M | -$72.2M | -$10.14 | -$79M |
| 2020 | $0 | -$88.3M | -$25.50 | -$57.5M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Solid Biosciences Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 6, 2026Activist stake changed SCHEDULE 13D/A
- November 4, 2026
- August 14, 2026Activist stake changed SCHEDULE 13D/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 6, 2026Other event 8-K
- August 6, 2026
- August 6, 2026
- August 6, 2026Passive stake (5% or more) SCHEDULE 13G
- July 30, 2026Passive stake (5% or more) SCHEDULE 13G
- June 24, 2026Activist stake changed SCHEDULE 13D/A
Insider trades
What the people running Solid Biosciences Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $24.6K worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 19, 2026 | Brooks GabrielChief Medical Officer | Soldpre-planned (10b5-1) | 4,374 | $24.6K |
| October 18, 2026 | Brooks GabrielChief Medical Officer | Exercised options | 9,750 | - |
| October 2, 2026 | Smith Ian FDirector | Exercised options | 3,440 | - |
| July 2, 2026 | Smith Ian FDirector | Exercised options | 3,440 | - |
| April 2, 2026 | Smith Ian FDirector | Exercised options | 3,441 | - |
| February 18, 2026 | Tan KevinCFO & Treasurer | Soldpre-planned (10b5-1) | 5,404 | $31.5K |
| February 18, 2026 | Brooks GabrielChief Medical Officer | Soldpre-planned (10b5-1) | 0 | $0 |
| February 18, 2026 | Howton David TChief Operating Officer | Soldpre-planned (10b5-1) | 7,469 | $43.5K |
Who owns SLDB
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| RA Capital Management, L.P.13D, may seek influence with 3 related filers | 11.9% | June 24, 2026 |
| Perceptive Advisors LLC13D, may seek influence with 3 related filers | 11.2% | August 14, 2026 |
| Raymond Debbane13G, passive with 7 related filers | 9.99% | May 5, 2026 |
| BCLS II Investco, LP13D, may seek influence with 5 related filers | 8.8% | March 10, 2026 |
| Fmr LLC13G, passive with 1 related filers | 7% | August 6, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 156 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| RA Capital Management, L.P. | 12,036,126 | +2,696,148 |
| Perceptive Advisors LLC | 11,906,646 | 0 |
| Bain Capital Life Sciences Investors, LLC | 9,808,819 | 0 |
| Siren, L.L.C. | 7,690,405 | 0 |
| BlackRock, Inc. | 6,934,248 | +1,975,894 |
| Fmr LLC | 6,875,957 | +3,269,553 |
| Armistice Capital, LLC | 4,278,000 | +1,078,000 |
| State Street Corp | 4,175,365 | +3,049,878 |
| Jupiter Topco LLC | 4,043,605 | new |
| Vanguard Capital Management LLC | 4,009,922 | +1,335,298 |
| Rtw Investments, LP | 3,892,926 | new |
| Deep Track Capital, LP | 3,565,062 | 0 |
| Franklin Resources Inc | 3,440,708 | +1,247,771 |
| Citadel Advisors LLC | 2,815,122 | +218,322 |
| Alyeska Investment Group, L.P. | 2,280,484 | +359 |
| Ameriprise Financial Inc | 2,225,783 | -213,066 |
| Vestal Point Capital, LP | 2,160,000 | -2,840,000 |
| Redmile Group, LLC | 1,948,695 | -63,200 |
| Geode Capital Management, LLC | 1,940,824 | +644,840 |
| Goldman Sachs Group Inc | 1,602,917 | +667,382 |
Insiders
8 insiders reported holding 952,457 shares in total, about $6.7M at the last price.
| Holder | Shares |
|---|---|
| Cumbo AlexanderPresident and CEO, Director | 235,405 |
| Smith Ian FDirector | 141,585 |
| Ganot IlanDirector | 126,77127,474 held indirectly |
| Howton David TChief Operating Officer | 105,077 |
| Tan KevinCFO & Treasurer | 99,422 |
| Brooks GabrielChief Medical Officer | 97,241 |
| Hanrahan JessieChief Regulatory Officer | 74,318 |
| Herzich PaulChief Technology Officer | 72,638 |
Questions about SLDB
What does Solid Biosciences Inc. do?
Solid Biosciences Inc. is a company in the Health care sector, listed on NASDAQ as SLDB. Its shares trade on NASDAQ under the ticker SLDB.
What is Solid Biosciences Inc.'s net worth?
Solid Biosciences Inc. has a market value (market cap) of $752.7M at the latest share price, and shareholders' equity of $342.1M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Solid Biosciences Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $215.3M.
When did Solid Biosciences Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 4, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the activist stake changed from November 6, 2026.
Similar companies
Compare SLDB with
Follow SLDB
Get an email when Solid Biosciences Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Solid Biosciences Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.